Together, these findings place ApoB at the intersection between hepatic lipid trafficking and systemic triglyceride excess, linking polygenic dyslipidemia to metabolic dysfunction-associated fatty liver disease (MASLD) and cardiometabolic risk. The gene discussed is APOB; the disease is metabolic dysfunction-associated steatotic liver disease.